homepage-banner.jpg
Mereo-Biopharma---logo.png

Unlocking healthcare potential for patients

Leveraging our expertise to address unmet medical needs

Our Strategy

Mereo BioPharma is an innovative leader in the biopharma sector with a focus on developing and optimizing the value of novel medicines acquired from large pharmaceutical companies designed to address significant unmet medical needs in rare and specialty disease areas.

Mereo BioPharma plans to build a rare and orphan disease commercial business based on products acquired from major pharmaceutical companies.

Find out more about our strategy

our products

Mereo has built an initial mid-late stage portfolio of four exceptionally well characterised novel products, three from Novartis and one from Astra Zeneca, for the treatment of diseases with considerable unmet medical need.

Each of these programmes has a comprehensive dataset for both pre-clinical and initial phase 2 clinical studies.

 

Phase 1
Phase 2a
Phase 2b
Phase 3

BPS-804 (SETRUSUMAB)

Osteogenesis Imperfecta (OI)
PHASE 2B (POTENTIALLY PIVOTAL)

AZD-9668 (ALVELESTAT)

Alpha-1 Antitrypsin Deficiency
PHASE 2

BGS-649 (LEFLUTROZOLE)

Hypogonadotropic Hypogonadism (HH) in Obese Men
Phase 2B

BCT-197 (acumapimod)

Acute Exacerbations of COPD
Phase 2

Investors

Share Price

View Share Price Chart

Events and conferences

  • 26 Sep 2017 Mereo BioPharma to present at the Cantor Global Healthcare Conference in New York, 25-27 September 2017
  • 19 May 2017 Mereo BioPharma presented at at the American Thoracic Society meeting in Washington, 19-24 May 2017
  • 02 Apr 2017 Mereo BioPharma presented at the Endocrine Society Annual meeting in Orlando, 01-04 April 2017
View All Events